LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Liminatus Pharma, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.11+0.07 (+2.30%)
Close on Oct 19, 2026
- Market cap
- $150.52M
- P/E (TTM)
- –
- Dividend yield
- –
Liminatus Pharma statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Market Cap | $208.87M | $166.30M |
| Enterprise Value | $207.29M | $88.19M |
| PB Ratio | 694.81 | 2.03 |
| P/TBV Ratio | 694.81 | 2.29 |
Income (trailing twelve months)
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Operating Income | -$4.07M | -$21.40M |
| Net Income | -$12.52M | -$22.46M |
| EBITDA | -$4.07M | -$16.91M |
| EPS (Diluted) | -$0.43 | -$0.83 |
Returns
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Return on Assets (ROA) | -471.5% | -40.9% |
| Return on Capital Employed (ROCE) | -1119.0% | -38.1% |
Balance sheet
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $3.02M | $61.43M |
| Total Debt | $1.44M | $118.52M |
| Net Cash (Debt) | $1.57M | $15.35M |
| Net Cash Per Share | $0.02 | $0.66 |
| Equity (Book Value) | $300.61K | $49.09M |
| Book Value Per Share | $0.00 | $1.37 |
| Tangible Book Value | $300.61K | $23.52M |
| Working Capital | $352.04K | $76.81M |
Financial position
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Current Ratio | 1.12 | 3.34 |
| Quick Ratio | 0.99 | 2.44 |
| Debt / Equity | 4.80 | 0.52 |
| Interest Coverage | -53.78 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Operating Cash Flow | -$3.97M | -$12.35M |
Efficiency
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Profits Per Employee | -$12.52M | -$703.34K |
| Employee Count | 1 | 74 |
Dividends and yields
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Earnings Yield | -6.00% | -23.3% |
Shares
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Shares Outstanding | 67,160,400 | 58,127,000 |
| Shares Change (YoY) | 82.7% | 10.9% |
| Shares Change (QoQ) | 24.7% | 0.54% |
| Float | 41,142,400 | 49,136,700 |
| Shares Held by Insiders | 38.7% | 11.6% |
| Shares Held by Institutions | 2.34% | 59.4% |
Scores
| Measure | Liminatus Pharma | Industry median |
|---|---|---|
| Altman Z-Score | 19.54 | -0.22 |
| Piotroski F-Score | 1 | 4 |
Calculated by StockData from Liminatus Pharma's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.